TG Therapeutics (TGTX) Short Interest Ratio & Short Volume $29.54 -1.30 (-4.22%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends TG Therapeutics Short Interest DataTG Therapeutics (TGTX) has a short interest of 32.00 million shares, representing 23.06% of the float (the number of shares available for trading by the public). This marks a -1.48% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.9, indicating that it would take 8.9 days of the average trading volume of 3.71 million shares to cover all short positions.Current Short Interest32,000,000 sharesPrevious Short Interest32,480,000 sharesChange Vs. Previous Month-1.48%Dollar Volume Sold Short$801.92 millionShort Interest Ratio8.9 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares155,660,000 sharesFloat Size138,750,000 sharesShort Percent of Float23.06%Today's Trading Volume3,275,262 sharesAverage Trading Volume3,708,598 sharesToday's Volume Vs. Average88% Short Selling TG Therapeutics? Sign up to receive the latest short interest report for TG Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTGTX Short Interest Over TimeTGTX Days to Cover Over TimeTGTX Percentage of Float Shorted Over Time Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov TG Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202432,000,000 shares $801.92 million -1.5%23.1%8.9 $25.06 10/15/202432,480,000 shares $798.03 million -5.6%23.5%9.2 $24.57 9/30/202434,400,000 shares $804.62 million +15.3%24.9%9.5 $23.39 9/15/202429,840,000 shares $708.10 million +1.1%21.6%8.2 $23.73 8/31/202429,510,000 shares $693.19 million -9.8%21.4%9.6 $23.49 8/15/202432,720,000 shares $685.16 million +5.0%23.7%11.4 $20.94 Get the Latest News and Ratings for TGTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202431,170,000 shares $615.92 million -3.1%22.6%11.2 $19.76 7/15/202432,180,000 shares $684.47 million -1.6%23.4%10.4 $21.27 6/30/202432,700,000 shares $581.73 million -2.6%23.8%10.6 $17.79 6/15/202433,560,000 shares $555.42 million +0.6%24.4%11 $16.55 5/31/202433,350,000 shares $543.61 million -2.8%24.2%10.9 $16.30 5/15/202434,300,000 shares $607.80 million -9.4%24.9%9.4 $17.72 4/30/202437,850,000 shares $517.03 million +6.0%27.1%10 $13.66 4/15/202435,710,000 shares $502.44 million +3.9%25.6%10.3 $14.07 3/31/202434,360,000 shares $522.62 million +0.5%24.7%7.9 $15.21 3/15/202434,190,000 shares $520.37 million -1.9%24.5%7.2 $15.22 2/29/202434,840,000 shares $599.94 million -2.6%25.0%6.7 $17.22 2/15/202435,780,000 shares $515.23 million +22.9%26.2%7.2 $14.40 1/31/202429,120,000 shares $472.91 million -5.2%21.4%5.6 $16.24 1/15/202430,700,000 shares $484.14 million -3.6%22.5%4.7 $15.77 12/31/202331,830,000 shares $543.66 million -12.8%23.2%5.2 $17.08 12/15/202336,520,000 shares $674.89 million +1.7%26.6%6.3 $18.48 11/30/202335,920,000 shares $460.14 million -1.9%26.2%6.4 $12.81 11/15/202336,610,000 shares $412.59 million -1.1%26.7%6.8 $11.27 10/31/202337,020,000 shares $286.16 million -0.5%27.0%6.8 $7.73 10/15/202337,210,000 shares $248.93 million +14.5%27.2%7.2 $6.69 9/30/202332,510,000 shares $271.78 million +10.2%23.7%6.5 $8.36 9/15/202329,510,000 shares $299.23 million +5.5%21.5%6 $10.14 8/31/202327,970,000 shares $292.85 million +1.6%20.4%5.8 $10.47 8/15/202327,520,000 shares $317.31 million +19.2%20.1%5.8 $11.53 7/31/202323,080,000 shares $477.53 million +3.3%16.9%5 $20.69 7/15/202322,340,000 shares $493.71 million -1.1%16.5%5.7 $22.10 6/30/202322,580,000 shares $560.89 million +0.4%16.7%5.5 $24.84 6/15/202322,480,000 shares $595.27 million +0.2%16.6%5.4 $26.48 5/31/202322,430,000 shares $597.31 million +3.0%16.6%5.2 $26.63 5/15/202321,770,000 shares $678.14 million -15.0%16.1%5.1 $31.15 4/30/202325,610,000 shares $635.90 million -6.7%19.3%5.8 $24.83 4/15/202327,460,000 shares $557.99 million -3.4%20.7%6.6 $20.32 3/31/202328,420,000 shares $427.44 million +6.6%21.5%6.3 $15.04 3/15/202326,650,000 shares $394.15 million +2.6%20.1%4.7 $14.79Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov 2/28/202325,970,000 shares $416.04 million +6.3%19.1%4.6 $16.02 2/15/202324,440,000 shares $472.67 million +4.2%18.1%4.5 $19.34 1/31/202323,450,000 shares $357.14 million +4.0%17.4%4.3 $15.23 1/15/202322,560,000 shares $307.49 million -3.3%16.7%4.4 $13.63 12/30/202223,340,000 shares $276.11 million +12.9%17.3%4.9 $11.83 12/15/202220,680,000 shares $178.26 million +6.9%15.3%7 $8.62 11/30/202219,350,000 shares $170.67 million -1.7%14.4%7.2 $8.82 11/15/202219,680,000 shares $173.38 million +2.3%14.6%7.6 $8.81 10/31/202219,230,000 shares $111.92 million -1.1%14.3%7.9 $5.82 10/15/202219,440,000 shares $105.56 million +5.8%14.5%7.6 $5.43 9/30/202218,380,000 shares $108.81 million +3.8%13.7%7 $5.92 9/15/202217,710,000 shares $129.28 million -3.1%13.2%6.6 $7.30 8/31/202218,270,000 shares $130.27 million -3.5%13.6%6.3 $7.13 8/15/202218,940,000 shares $159.10 million -7.1%14.1%5.9 $8.40 7/31/202220,380,000 shares $122.08 million -2.3%15.3%6.2 $5.99 7/15/202220,860,000 shares $129.33 million +0.2%28.8%6.6 $6.20 6/30/202220,810,000 shares $88.44 million +2.5%28.7%6.3 $4.25 6/15/202220,310,000 shares $78.60 million +5.6%28.0%6.4 $3.87 5/31/202219,240,000 shares $85.04 million -2.6%14.4%6.5 $4.42 5/15/202219,760,000 shares $128.44 million +1.2%14.8%7.8 $6.50 4/30/202219,530,000 shares $135.54 million +0.8%14.8%8.3 $6.94 4/15/202219,370,000 shares $171.42 million -8.1%14.6%6.9 $8.85 3/31/202221,070,000 shares $200.38 million +11.0%15.9%8.5 $9.51 3/15/202218,980,000 shares $151.65 million -3.8%14.3%7.8 $7.99 2/28/202219,720,000 shares $194.64 million +4.0%14.9%8.4 $9.87 2/15/202218,970,000 shares $207.34 million +13.9%14.3%7.1 $10.93 1/31/202216,660,000 shares $192.76 million +2.0%12.5%6.4 $11.57 1/15/202216,340,000 shares $256.37 million +6.4%12.3%8.6 $15.69 12/31/202115,360,000 shares $291.84 million +5.8%N/A8.8 $19.00 12/15/202114,520,000 shares $242.77 million +8.5%11.0%8.9 $16.72 11/30/202113,380,000 shares $203.38 million -1.2%10.1%8.7 $15.20 11/15/202113,540,000 shares $366.26 million +0.6%10.2%11.6 $27.05 10/29/202113,460,000 shares $420.22 million -1.7%10.2%10.7 $31.22 10/15/202113,690,000 shares $456.01 million +1.3%10.4%9.1 $33.31 9/30/202113,520,000 shares $449.95 million +4.1%10.2%8.9 $33.28 9/15/202112,990,000 shares $388.40 million -6.2%9.8%8.6 $29.90 8/31/202113,850,000 shares $374.92 million +8.0%10.5%9.4 $27.07 8/13/202112,820,000 shares $292.17 million +12.2%9.7%9.2 $22.79 7/30/202111,430,000 shares $399.94 million +3.5%8.7%8.6 $34.99 7/15/202111,040,000 shares $411.02 million +2.5%8.4%9.8 $37.23 6/30/202110,770,000 shares $417.77 million -5.8%8.2%8.5 $38.79 6/15/202111,430,000 shares $427.60 million -2.8%8.7%8.3 $37.41 5/28/202111,760,000 shares $410.07 million +1.8%8.9%8.3 $34.87 5/14/202111,550,000 shares $395.47 million +2.6%8.8%8 $34.24 4/30/202111,260,000 shares $484.41 million +0.8%8.5%7.7 $43.02 4/15/202111,170,000 shares $497.85 million -5.4%8.5%7.5 $44.57 3/31/202111,810,000 shares $534.76 million -1.3%9.0%8.1 $45.28 3/15/202111,960,000 shares $595.97 million +1.0%9.1%7.9 $49.83 2/26/202111,840,000 shares $515.04 million +0.7%9.1%5.7 $43.50 2/12/202111,760,000 shares $574.01 million -2.1%9.2%5.8 $48.81Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov 1/29/202112,010,000 shares $577.08 million -4.4%9.4%5.9 $48.05 1/15/202112,560,000 shares $642.95 million No Change9.8%6.3 $51.19 1/31/202013,860,000 shares $196.95 million +7.8%16.1%6.4 $14.21 1/15/202013,860,000 shares $195.43 million +7.8%16.1%6.4 $14.10 12/31/201912,860,000 shares $142.75 million +0.9%14.9%6.6 $11.10 TGTX Short Interest - Frequently Asked Questions What is TG Therapeutics' current short interest? Short interest is the volume of TG Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 32,000,000 shares of TGTX short. 23.06% of TG Therapeutics' shares are currently sold short. Learn More on TG Therapeutics' current short interest. What is a good short interest ratio for TG Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TGTX shares currently have a short interest ratio of 9.0. Learn More on TG Therapeutics's short interest ratio. Which institutional investors are shorting TG Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of TG Therapeutics: Jane Street Group LLC, Wolverine Trading LLC, Point72 Asset Management L.P., Walleye Trading LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for TG Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.06% of TG Therapeutics' floating shares are currently sold short. Is TG Therapeutics' short interest increasing or decreasing? TG Therapeutics saw a decline in short interest during the month of October. As of October 31st, there was short interest totaling 32,000,000 shares, a decline of 1.5% from the previous total of 32,480,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is TG Therapeutics' float size? TG Therapeutics currently has issued a total of 155,660,000 shares. Some of TG Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TG Therapeutics currently has a public float of 138,750,000 shares. How does TG Therapeutics' short interest compare to its competitors? 23.06% of TG Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to TG Therapeutics: Deciphera Pharmaceuticals, Inc. (5.71%), Sage Therapeutics, Inc. (11.91%), FibroGen, Inc. (4.29%), Insmed Incorporated (7.74%), Summit Therapeutics Inc. (2.31%), Genmab A/S (0.37%), Viatris Inc. (2.09%), Vaxcyte, Inc. (7.16%), Dr. Reddy's Laboratories Limited (1.28%), Sarepta Therapeutics, Inc. (5.86%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short TG Therapeutics stock? Short selling TGTX is an investing strategy that aims to generate trading profit from TG Therapeutics as its price is falling. TGTX shares are trading down $1.30 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against TG Therapeutics? A short squeeze for TG Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TGTX, which in turn drives the price of the stock up even further. How often is TG Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TGTX, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Deciphera Pharmaceuticals Short Interest Sage Therapeutics Short Interest FibroGen Short Interest Insmed Short Interest Summit Therapeutics Short Interest Genmab A/S Short Interest Viatris Short Interest Vaxcyte Short Interest Dr. Reddy's Laboratories Short Interest Sarepta Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TGTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TGTX Stock Alerts